Cathepsin L is a lysosomal cysteine proteinase primarily devoted to the metabolic turnover of intracellular proteins. However, accumulating evidence suggests this endopeptidase may be also implicated in the regulation of other important biological functions including bone resorption in normal and pathological conditions. These findings support the concept that cathepsin L, in concert with other proteolytic enzymes involved in bone remodelling processes, may contribute to facilitate bone metastasis formation. In support of this hypothesis, recent studies indicate that cathepsin L may foster this process by triggering multiple mechanisms which, in part, differ from those of the major cysteine proteinase of osteoclast, namely cathepsin K. Therefore, cathepsin L may be regarded as an additional target in the treatment of patients with metastatic bone disease. This review discusses the clinical and therapeutic implications related to these findings.
Leto, G., Sepporta, M.V., Crescimanno, M., Flandina, C., Tumminello, F.M. (2010). Cathepsin L in metastatic bone disease: therapeutic implications. BIOLOGICAL CHEMISTRY, 391(6), 655-664 [10.1515/BC.2010.069].
Cathepsin L in metastatic bone disease: therapeutic implications
LETO, Gaetano;CRESCIMANNO, Marilena;FLANDINA, Carla;TUMMINELLO, Francesca Maria
2010-01-01
Abstract
Cathepsin L is a lysosomal cysteine proteinase primarily devoted to the metabolic turnover of intracellular proteins. However, accumulating evidence suggests this endopeptidase may be also implicated in the regulation of other important biological functions including bone resorption in normal and pathological conditions. These findings support the concept that cathepsin L, in concert with other proteolytic enzymes involved in bone remodelling processes, may contribute to facilitate bone metastasis formation. In support of this hypothesis, recent studies indicate that cathepsin L may foster this process by triggering multiple mechanisms which, in part, differ from those of the major cysteine proteinase of osteoclast, namely cathepsin K. Therefore, cathepsin L may be regarded as an additional target in the treatment of patients with metastatic bone disease. This review discusses the clinical and therapeutic implications related to these findings.File | Dimensione | Formato | |
---|---|---|---|
GALLEY PROOF CATH L REWBIOLCHEM-09-346.pdf
Open Access dal 01/07/2010
Dimensione
193.23 kB
Formato
Adobe PDF
|
193.23 kB | Adobe PDF | Visualizza/Apri |
CATH L REV BIOL CHEM 2010.pdf
Solo gestori archvio
Dimensione
97.48 kB
Formato
Adobe PDF
|
97.48 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.